Structural Heart and Coronary Trials in…

Europe remains one of the most attractive regions for structural heart and coronary device trials. The combination of experienced investigators, advanced clinical infrastructure, and access to diverse patient populations creates significant opportunities for sponsors to develop innovative cardiovascular technologies.

Yet, behind many delayed timelines, escalating budgets, and underperforming studies lies a common issue: underestimating the operational complexity of executing these trials across Europe.

Structural heart and coronary studies are among the most demanding clinical investigations in medical devices. They involve technically complex procedures, highly selected patient populations, imaging-intensive endpoints, long-term follow-up requirements, and increasingly rigorous regulatory scrutiny. When these elements intersect with Europe's fragmented regulatory and healthcare landscape, even well-designed studies can quickly encounter major challenges.

The question is rarely whether problems can occur. The question is whether they are anticipated early enough to prevent them from jeopardizing the study.

Fast Recruitment: Reality vs. Illusion

One of the most common pitfalls begins during feasibility. High-volume centers are often assumed to be high-enrolling centers. In reality, procedural volume alone says very little about recruitment potential for a specific clinical trial.

Structural heart studies may involve narrow eligibility criteria, extensive cardiac imaging and screening, multidisciplinary heart teams, and, in many cases, competition from commercial therapies or parallel studies. As a result, enrollment projections do not consistently align with operational reality.

In coronary studies, patients may appear readily available, but operational execution often becomes a bottleneck. Hospitals and sites can struggle with timely patient screening in acute settings, availability of research staff during off-hours procedures, and integration of randomization workflows within cath labs.

Without careful validation of operational reality at site level, recruitment timelines can drift months beyond original expectations.

How Regulatory Delays Cascade Across the Study

Europe's regulatory environment requires detailed coordination of clinical trial applications across countries, ethics committees, and competent authorities. Even small inconsistencies in submission packages can cause delays across the entire study timeline.

Common issues include:

Misalignment in country submission strategies
Underestimation of MDR-related documentation requirements
Delayed or incorrect responses to institutions
Delays in site activation despite regulatory approval

In multi-country trials, delays in one region often impact planning, execution, and decision-making across the entire study.

What makes this particularly challenging is that timelines on paper rarely reflect operational reality. Local interpretation of regulations, institutional review procedures, and administrative requirements can vary substantially between countries, and sometimes even between sites within the same country.

Because planned timelines rarely capture real-world regulatory and site variability, sponsors should proactively build contingency, regional insight, and early alignment into study planning to reduce downstream delays.

Cardiac Imaging Variability: A Hidden Risk

In structural heart and coronary trials, imaging is not just supportive data; it is often the foundation of primary and secondary endpoints.

Yet imaging-related risks are frequently underestimated. Differences in acquisition protocols, equipment calibration, operator expertise, and image transfer processes can create inconsistencies that compromise endpoint evaluation and increase query rates during trial analysis.

In some cases, poor imaging standardization leads to repeat procedures, exclusion of evaluable data, delays in core lab adjudication, and reduced statistical robustness of endpoints.

Because these issues often surface only after enrollment begins, sponsors should identify and address potential risks during study start-up to prevent disruption later in the study.

Investigator Engagement Can Decline Quickly

Initial investigator enthusiasm does not always translate into sustained study performance, meaning continued enrollment, credible timelines, and operational execution that remains aligned with plan.

If operational support is insufficient, even experienced centers may deprioritize the study in favor of routine clinical activity or competing trials.

This is particularly critical in Europe, where many leading cardiovascular centers participate in multiple global device studies simultaneously. Without proactive site engagement strategies, recruitment momentum can decline rapidly after the initial activation phase.

Contracts and Budgets: The Underestimated Bottleneck

Sponsors are often surprised by how long contract negotiations can delay activation, even after regulatory approvals are secured.

Across Europe, negotiations may involve hospital legal departments, university administrations, and/or regional healthcare authorities.

Budget expectations also vary significantly between countries and institutions. Failure to account for local cost structures can create prolonged negotiation cycles and weaken site trust and engagement before enrollment even begins.

The consequence is not just delay. Addressing site activation planning early helps protect recruitment timelines and prevents over-reliance on already activated sites.

Follow-Up Challenges and Data Quality Risks

Structural heart and coronary studies frequently require long-term follow-up. Maintaining patient retention and data completeness across multiple countries introduces another layer of operational risk.

Common challenges include:

Missed follow-up visits
Variability in standard-of-care assessments
Patient movement between healthcare providers and/or hospitals
Incomplete adverse event reporting
Missing patient-specific information and documentation

Without strong oversight and proactive data management strategies, gaps accumulate gradually and often become visible only when database lock approaches.

Sponsors can significantly reduce cost and complexity by identifying and resolving data gaps early through proactive monitoring and data management.

Why Experience Changes Outcomes

Many of these pitfalls are not caused by poor study design. They arise from operational assumptions that fail under real-world conditions.

The difference between a study that remains on track and one that struggles often comes down to whether the operational strategy was built by teams with:

Deep cardiovascular device expertise
Country-level regulatory understanding
Established site relationships
Experience managing imaging-intensive trials
The ability to identify risks before they materialize

In Europe, successful execution requires more than clinical trial management. It requires navigating a highly fragmented environment while maintaining consistency and quality across all moving parts.

This is where an experienced CRO partner, such as QbD Group, becomes critical.

Organizations with specialized expertise in structural heart and coronary studies bring not only operational support, but also the ability to challenge assumptions early, apply realistic feasibility assessments, and proactively address risks before they impact timelines.

Moving from Insights to Action

Europe offers significant opportunities for structural heart and coronary trials, but it is not a plug-and-play environment. Complexity exists at every level: regulatory, operational, clinical, and logistical.

The most successful studies are not necessarily those with the largest budgets or the most ambitious timelines. They are the studies built on realistic planning, proactive risk management, and experienced execution.

In a field where every delay directly impacts development milestones, investment decisions, and ultimately patient access to innovation, selecting the right operational partner is no longer a secondary consideration; it is a strategic decision.